Detalhe da pesquisa
1.
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.
Cancer
; 129(8): 1195-1204, 2023 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36748723
2.
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.
Gynecol Oncol
; 166(2): 211-218, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35361487
3.
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Lancet Oncol
; 21(10): 1353-1365, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32919526
4.
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
Int J Cancer
; 147(8): 2190-2198, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32359091
5.
Tumour mutational burden in treatment-resistant tumours - Authors' reply.
Lancet Oncol
; 21(12): e552, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33271109
6.
Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents.
Virchows Arch
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38388965
7.
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
J Clin Oncol
; 40(7): 752-761, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34990208
8.
Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study.
Eur J Cancer
; 171: 259-268, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35777186
9.
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.
Eur J Cancer
; 169: 188-197, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35588692
10.
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.
Lancet Gastroenterol Hepatol
; 7(5): 446-454, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35114169
11.
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.
Lancet Respir Med
; 9(6): 613-621, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33836153
12.
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.
Clin Cancer Res
; 26(9): 2124-2130, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31980466
13.
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
J Thorac Oncol
; 15(4): 618-627, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31870883
14.
Well-differentiated neuroendocrine tumor of the stomach: A rare case at an uncommon site.
Medicine (Baltimore)
; 95(29): e4260, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27442656
15.
Altered phenotype and reduced function of muscle-derived hematopoietic stem cells.
Exp Hematol
; 31(9): 806-14, 2003 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12962727
16.
An in vivo propagated human acute myeloid leukemia expressing ABCA3.
Leuk Res
; 28(3): 295-9, 2004 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-14687625
17.
Differential mRNA processing in hematopoietic stem cells.
Stem Cells
; 24(3): 662-70, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16373690